Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials
Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…
AI Summary: Novo Nordisk’s much‑talked‑about GLP‑1 drug, famed for its weight‐loss benefits, has hit an unexpected wall in Alzheimer’s trials. In two separate reports – one on the standard injectable and another on a pill form – semaglutide showed no statistically significant impact on slowing brain decline. Who knew obesity meds couldn’t multitask?
FDA Approves Pembrolizumab + Enfortumab Vedotin-ejfv for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
oncodaily - What Does FDA Approval Mean? The U.S. Food and Drug Administration (FDA) evaluates new cancer therapies to determine whether they are safe and effective for clinical use. Approval is based […]
AI Summary: The U.S. Food and Drug Administration has approved a combination of pembrolizumab (Keytruda) and enfortumab vedotin (Padcev) for patients with muscle‐invasive bladder cancer who cannot tolerate cisplatin. Both agents—which have individually transformed treatment paradigms—are now linked in a perioperative setting that could alter outcomes for this aggressive cancer.
New nasal nanodrops wipe out brain tumors in mice
sciencedaily - A new nasal-delivered nanotherapy shows promise against aggressive glioblastoma tumors. By activating the STING immune pathway using gold-core spherical nucleic acids, researchers were able to reach the brain without invasive surgery. When paired with dru…
AI Summary: A novel nasal‐delivered nanotherapy that triggers the STING immune pathway via gold‐core nanoparticles has been shown in mice to nearly wipe out aggressive brain tumors. This noninvasive approach offers hope for a radically new treatment modality in glioblastoma.
FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation
esmo - Evidence for efficacy is based on the results from the KO-MEN-001 study
AI Summary: The FDA has granted full approval for ziftomenib—a novel agent aimed at treating relapsed or refractory acute myeloid leukemia, especially in patients with NPM1 mutations. Backed by the KO‐MEN‐001 trial data, this decision marks a significant step forward for a patient group in dire need of new therapeutic options.
Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns
Alex Hoffman / endpoints - → In what appears to be another blow to Novo Nordisk, ex-Pfizer CSO Mikael Dolsten has withdrawn his nomination to join the company's board of directors due to ...
AI Summary: Merck has made a blockbuster move by finalizing a $9.2 billion deal to acquire Cidara Therapeutics’ late‐stage anti‐influenza candidate. This acquisition underscores Merck’s commitment to expanding its antiviral portfolio and marks a key strategic investment in advancing flu prevention amid evolving global health threats.
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
go - The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year
AI Summary: The FDA has revised the label for Sarepta’s Duchenne muscular dystrophy gene therapy, adding a boxed safety warning and stricter usage conditions following reports of two patient deaths. The update reflects mounting safety concerns that have prompted closer regulatory oversight.
Bacteria Inside Brain Tumors May Affect Tumor Behavior
oncodaily - Traces of bacteria inside brain tumors may affect tumor behavior Researchers found bacterial genetic and cellular elements inside brain tumor cells that appear biologically active and may influence tumor progression […]
AI Summary: Researchers discovered unexpected traces of bacteria within brain tumors, suggesting these microbial signals might influence tumor progression. The findings, detailed in two nearly identical reports, could open new avenues for targeted therapies and a deeper understanding of the tumor microenvironment.
Richard Pazdur Appointed Director of the FDA’s Drug Center: A New Chapter for Cancer Regulation
oncodaily - Dr. Richard Pazdur, one of the most influential figures in oncology drug regulation, has been appointed Director of the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and […]
AI Summary: The FDA has ushered in a new era in oncology drug oversight by appointing Dr. Richard Pazdur as the director of its Drug Center. The move comes amid agency challenges and staff cuts, promising stabilizing leadership at one of its most influential divisions.
Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera
Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…
AI Summary: In a dramatic showdown over obesity biotech firm Metsera, Pfizer’s up-to-$10B cash offer edged out Novo Nordisk’s bid. The fiercely competitive deal highlights the high stakes and intense market focus on innovative therapeutics in obesity management.
Pfizer poised to buy Metsera in $10 bn deal after bidding war
medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.
AI Summary: In a dramatic bidding war for a promising biotech startup, Pfizer’s improved $10 billion offer prevailed—until Novo Nordisk raised its bid yet again. This high-stakes takeover tussle underscores the fierce competition and strategic importance of emerging therapies.